CVS Health Corp

CVS Health shares have climbed more than 18% year to date, outpacing the S&P 500's sub-13% gain, and Wall Street analysts see further upside with a consensus price target of $114.59 per share, about 22% above the latest close. The company beat adjusted earnings estimates in both the first and second quarters, posting $2.57 per share versus a $2.21 consensus in Q1 and $2.58 versus $1.83 in Q2, while raising full-year guidance each time. A sharp improvement in the medical benefit ratio at its Aetna-led healthcare benefits segment, which fell from 94.8% in the fourth quarter of 2025 to 84.6% in Q1 and 87.4% in Q2, drove adjusted operating income up 52% year over year to over $3 billion in the first quarter and 85% to $2.4 billion in the second. Sixteen of 17 analysts tracked by TipRanks rate the stock a buy, with UBS's Kevin Caliendo lifting his price target to $126 from $122 after the second-quarter report.

Falling prescription drug prices dragged Walmart's U.S. comparable sales down 80 to 90 basis points, masking what would otherwise have been roughly 3.4% growth. Target's 3.8% comparable sales outpaced Walmart's 2.6% because it sold its pharmacy business to CVS for $1.9 billion in 2015, sidestepping drug-price deflation entirely. Walmart's transaction growth slowed to 1.5% from 3%, signaling lower-income shoppers are making fewer trips even as higher-income consumers trade down to Walmart.

CVS Health raised its 2026 earnings and cash-flow outlook after second-quarter adjusted earnings rose 42.5% to $2.58 per share and revenues increased 7.3% to $106.10 billion. The company lifted its 2026 adjusted EPS guidance to $7.90-$8.10 from $7.30-$7.50, with consolidated revenues of at least $414 billion and adjusted operating income of $16.58-$16.92 billion. Expected cash flow from operations rose to at least $11.5 billion from at least $9.5 billion. The Aetna Health Care Benefits segment drove the improvement, with second-quarter adjusted operating income up 85.5% to $2.43 billion and its medical benefit ratio improving to 87.4% from 89.9%. CVS also raised that segment's 2026 adjusted operating income outlook to $5.03-$5.37 billion, more than $1 billion above prior guidance, while management cautioned that the medical benefit ratio is expected to rise materially through the second half and that 2027 pharmacy-services headwinds remain.

CVS Health is expanding its consumer health care technology initiatives, including the targeted launch of its Health100 platform and an AI-powered assistant called Haio. The company committed last year to invest $20 billion over the next decade in emerging technologies to simplify the health care experience and improve customer engagement. CVS expects to expand access to the platform later this year following encouraging early feedback. The company also launched an AI-enabled claims assist manager expected to reduce processing time by more than 20% and accelerate payments for providers on hundreds of millions of claims annually. CVS shares have risen 19.6% year to date, compared with the industry's 1.2% growth, and the stock carries a Zacks Rank #2 (Buy).

CVS Health is rolling out new digital tools for its pharmacy benefit manager clients to manage pharmacy benefits and monitor prescription spending, citing a new CVS Caremark survey showing employers have higher trust in PBMs to manage drug costs and access to complex treatments. The company is also expanding coverage for biosimilars and GLP-1 therapies across its pharmacy network with a focus on affordability, aiming to support employers and payers facing rising specialty drug spending. The rollout follows second-quarter 2026 results that showed revenue of US$106.10 billion and net income of US$2.98 billion, along with an increase in 2026 GAAP diluted EPS guidance to a range of US$6.84 to US$7.04. Investors will watch for PBM client retention, GLP-1 prescription trends, and any revision to the 2026 earnings guidance or the revenue outlook of at least US$414.0 billion.

CVS Health announced a revamp of its weight management program to improve access, affordability, and support for GLP-1 medications. The company is collaborating with Eli Lilly and Company to provide eligible Zepbound and Foundayo patients an additional access point at CVS Pharmacy through the CVS Health app, with transparent pricing including cash-pay options expected by early fourth quarter of 2026. CVS Pharmacy offers all FDA approved GLP-1s, and MinuteClinic digital weight loss visits have been lowered to $29, the most affordable option in the market, available 24/7 with no membership or recurring monthly fee. The program combines an online visit with a licensed clinician, same-day medication pickup at 9,000 local CVS Pharmacy locations, and in-person pharmacist support in one connected experience. CVS Pharmacy also participates in the Centers for Medicare & Medicaid Services Medicare GLP-1 Bridge program, which runs through December 31, 2027, offering eligible Medicare beneficiaries certain GLP-1 medications for $50 per month.

UnitedHealth Group reported second-quarter results showing its medical care ratio fell to 86.7% from 89.4% a year ago, helping operating earnings rise 55% and prompting the company to raise its 2026 adjusted EPS guidance. The quarter included $860 million of favorable prior-period medical development, while commercial medical costs are increasing at a rate exceeding 11% due to higher provider billing and coding intensity and specialty drug costs. Elevance Health's second-quarter benefit expense ratio was 89.7%, up 80 basis points year over year, but the company raised its 2026 adjusted EPS guidance to at least $27. CVS Health's Aetna business benefited from lower medical costs in the second quarter, leading to an earnings beat and raised 2026 adjusted EPS guidance of $7.90 to $8.10. UnitedHealth shares have risen 47.9% in the past 12 months, and the stock trades at a forward price-to-earnings ratio of 18.83X compared with the industry average of 16.48X.

CVS Health reported second quarter 2026 adjusted earnings per share of $2.58, exceeding expectations and prompting the company to raise its full-year adjusted EPS guidance by $0.60 to a range of $7.90 to $8.10. The company also increased its full-year cash flow from operations outlook to at least $11.5 billion, up $2 billion from prior guidance. Adjusted operating income rose 35% year over year to $5.2 billion, with all operating segments growing earnings. CVS Health also provided preliminary 2027 commentary, stating that an adjusted EPS of at least $8.44 appears reasonable, representing about 13% growth off an adjusted baseline of $7.46.

Eighty-six percent of S&P 500 companies that have reported quarterly results so far beat earnings-per-share estimates, while 79% posted year-over-year profit growth. Out of 133 reporting firms, 114 topped consensus EPS forecasts, 15 fell short, and 4 met expectations, with 105 delivering higher earnings than a year ago. On the revenue side, 97 companies exceeded sales projections and 36 missed, while 110 achieved year-over-year top-line expansion. Notable movers included Palantir Technologies, which rallied 29.5% after revenue soared 94% to $1.94 billion, and Advanced Micro Devices, which dropped 7.04% despite a 50% revenue surge to a record $11.54 billion. Other highlights featured CVS Health raising its full-year 2026 adjusted EPS guidance to $7.90–$8.10, Pfizer lifting its 2026 revenue forecast to $60.5 billion–$62.5 billion, and Disney reaffirming its roughly 12% full-year adjusted EPS growth outlook while boosting its fiscal 2026 buyback target to at least $9 billion.

CVS Health raised its 2026 earnings guidance and expanded its GLP-1 weight management collaboration with Eli Lilly, the company announced alongside second-quarter results. Revenue reached US$106.10 billion with net income of US$2,979 million, while sales came in at US$35,117 million. The expanded collaboration leverages CVS's integrated pharmacy, insurance, and care-delivery assets to capture growing demand for weight management treatments. The raised guidance reinforces near-term confidence in margin recovery, though elevated medical and pharmacy cost trends remain a key risk.

SpaceX shares fell 11% in premarket trading after the Elon Musk-led rocket company released its first quarterly report since going public in June, reporting capital expenditures of $18.37 billion, up 550% from a year ago, while second-quarter revenue of $7.81 billion topped estimates. Disney rose more than 3% despite mixed fiscal third-quarter results, with earnings per share beating expectations but revenue slightly missing, and its experiences business revenue up 10% annually. Arista Networks gained 12% after second-quarter adjusted earnings of $1.02 per share on revenue of $3.04 billion surpassed estimates, and third-quarter guidance also beat. AMD plunged 8.5% as second-quarter adjusted earnings of $1.66 per share on revenue of $11.54 billion and in-line third-quarter revenue guidance of $13 billion failed to impress investors. Eli Lilly jumped more than 6.5% after beating earnings and revenue estimates and raising its full-year 2026 revenue guidance, driven by surging demand for weight loss drug Zepbound and diabetes treatment Mounjaro. Circle Internet Group shares were up more than 5% after naming initial partners for its Arc blockchain and doubling the midpoint of its full-year other revenue guidance to $320 million. Wynn Resorts saw shares jump 5% after second-quarter adjusted earnings of $1.24 per share on revenue of $1.86 billion beat estimates. CVS Health shares were up over 2.5% after better-than-expected earnings and revenue and an increase in its 2026 adjusted earnings per share guidance to a range of $7.90 to $8.10. Kratos Defense & Security Solutions rose 10% after second-quarter revenue beat estimates in all segments. Pinterest slid nearly 9% as third-quarter revenue guidance of $1.19 billion to $1.21 billion, bracketing the consensus estimate of $1.2 billion, failed to impress despite second-quarter beats. DaVita fell over 5.5% even with better-than-expected second-quarter results, as full-year adjusted earnings guidance of $14.10 to $15.20 per share compared to a consensus of $14.88. Teradata slumped 13% after third-quarter earnings guidance of 55 to 59 cents per share excluding items trailed the consensus estimate of 62 cents. Booking Holdings advanced more than 7% after second-quarter gross bookings of $51 billion and adjusted earnings of $2.54 per share on revenue of $7.35 billion topped estimates. Uber Technologies fell 3% after third-quarter bookings guidance of $59.25 billion at the midpoint missed the consensus estimate of $59.33 billion. Carlyle Group rose more than $2 after earnings and revenue beat estimates and total assets under management reached $485 billion. Flutter Entertainment was off more than 5% after announcing CEO Peter Jackson would leave and be replaced by Dan Taylor on October 1, and lowering full-year revenue guidance.

CVS Health announced a revamp of its weight management program, introducing a $29 MinuteClinic online visit for GLP-1 therapy evaluation and a collaboration with Eli Lilly to offer transparent pricing for Zepbound and Foundayo through the CVS Health app. The $29 visit, available 24/7 with no membership or recurring fee, connects eligible adults with licensed clinicians who can prescribe GLP-1 medications when clinically appropriate, with same-day pickup at 9,000 CVS Pharmacy locations. Through the Lilly collaboration, eligible Zepbound and Foundayo patients will be able to view transparent cash-pay and reimbursed pricing in the app by early fourth quarter of 2026. CVS Pharmacy already offers all FDA-approved GLP-1s, with out-of-pocket costs as low as $25 per month through commercial insurance with a manufacturer coupon, or $149 for uninsured patients using a manufacturer voucher. The company also participates in the Medicare GLP-1 Bridge program, offering certain medications for $50 per month to eligible beneficiaries through December 31, 2027.

US companies are gradually dropping coverage for GLP-1 weight-loss drugs such as Wegovy and Zepbound, pushing more patients to buy medications through direct-to-consumer platforms. This opens the door for retail giants like Walmart, Costco, CVS, and Amazon to rapidly expand health services and draw customers into their own ecosystems. Analysts view the monthly refill prescriptions as a tool for building long-term customer relationships. Eric Bormel, managing director of digital health at Solomon Partners, says retailers are competing to become the first point of care for obesity patients. Meanwhile, drugmakers like Eli Lilly and Novo Nordisk have launched DTC programs with price promotions, such as LillyDirect charging around 299 to 449 dollars per month and NovoCare starting at just 199 dollars per month. Costco has partnered with Sesame to sell Wegovy for about 349 dollars per month for members. Walmart, with roughly 4,600 pharmacies, has expanded its Better Care Services platform to become a comprehensive health service hub. Amazon offers medication starting at just 25 dollars per month through Amazon Pharmacy, with same-day delivery in nearly 3,000 cities. A Mercer survey indicates that 6 percent of large employers dropped GLP-1 drug coverage this year after treatment costs surged, with the share of claims for this drug class rising to 11.4 percent from 6.9 percent in 2023. This intensifies competition among retailers and puts heavy pressure on independent pharmacies.

X and the World Federation of Advertisers have settled litigation over an alleged advertiser boycott linked to the now-defunct Global Alliance for Responsible Media. The settlement follows a March ruling in which a U.S. judge dismissed X's antitrust lawsuit against the WFA and major companies including Mars, CVS Health, and Colgate-Palmolive. The WFA reaffirmed its commitment to freedom of speech and said it had permanently discontinued GARM in August 2024 and would not revive the initiative or create a similar program. The two organizations said brands, platforms, and consumers all stand to benefit from continued innovation in brand safety.

Health100, a CVS Health subsidiary, has earned the CARIN Code of Conduct for Consumer-Facing Applications Accreditation from DirectTrust for its mobile app. The accreditation followed a comprehensive independent third-party review that examined the app's transparency, consent, use and disclosure, individual access, security, provenance, accountability, and education. DirectTrust President and CEO Scott Stuewe said the achievement gives all health care stakeholders full confidence in exchanging private health information via the app. Tony Ambrozie, Senior Vice President and Chief Digital & Technology Officer at CVS Health and Health100, called the accreditation an important milestone that reinforces the company's commitment to data privacy, security, and transparency. Health100 provides consumers with cost transparency, care navigation, and chronic condition management through a unified platform open to all consumers regardless of where they get their care.

CVS Health is expected to report a year-over-year increase in earnings and revenue for the quarter ended June 2026, with the Zacks Earnings ESP model indicating a likely beat. The consensus estimate calls for earnings of $1.87 per share, up 3.3% from the prior year, on revenues of $100.18 billion, a 1.3% increase. The Most Accurate Estimate is higher than the consensus, yielding an Earnings ESP of +1.42%, and the stock carries a Zacks Rank of 2, a combination that historically produces a positive surprise nearly 70% of the time. CVS Health has beaten consensus EPS estimates in each of the last four quarters, including a 16.29% surprise in the most recent period. The company is scheduled to release results on August 5.

CVS Health announced that common prescription medications for dogs and cats are now available at its approximately 9,000 CVS Pharmacy locations nationwide. Pet owners can fill prescriptions for select pet-only medications, including antibiotics, allergy, flea and tick control, insulin, and pain relievers, and can manage eligible pet prescriptions through the CVS Health app. The service offers the same pharmacy conveniences as human prescriptions, such as automatic refills, prescription syncing, and delivery for select medications. Pet owners can present a written prescription or have their veterinarian contact the pharmacy directly, with electronic prescription capabilities planned for the coming months. The move expands CVS Pharmacy's pet care offerings, which already include a range of pet food, grooming tools, and wellness products in stores and online.

Kate Farms announced the continued national retail expansion of its High Protein Nutrition Shake, with availability expected to exceed 6,800 Walmart and CVS stores by August. The company also unveiled a new Vanilla flavor, joining existing Chocolate and Strawberry offerings. Since launching in Walmart in Q4 2025, retail distribution for the shake has grown more than sevenfold. The expansion comes as the global plant-based protein market is projected to reach nearly $35 billion by 2030 and GLP-1 usage scales across the U.S., driving consumer demand for high-protein, nutrient-dense options. Kate Farms products are used in more than 1,500 hospitals and medical settings nationwide.

Mark Farrah Associates has released a comparative analysis of the top Administrative Services Only companies in Maryland, identifying UnitedHealth, CareFirst, CVS, and Cigna as the four leading administrators based on number of contracts. Together, these four companies cover 98 percent of the state's self-insured marketplace. CareFirst is the largest administrator in Maryland, while UnitedHealth covers employers in all counties and is the top administrator in six of those counties. CVS and Cigna also maintain a large ASO presence for employer contracts but do not cover as many counties as CareFirst and UnitedHealth.

Zacks Investment Research has identified four medical-sector companies with the right setup to beat second-quarter earnings expectations. The picks are CVS Health, Cardinal Health, Humana, and ACADIA Pharmaceuticals, each combining a positive Earnings ESP with a Zacks Rank of 1 or 2. Humana carries a Zacks Rank of 1 and an Earnings ESP of plus 1.71 percent, with consensus revenue estimates of 40.65 billion dollars implying 25.5 percent growth. CVS Health holds a Zacks Rank of 2 and an Earnings ESP of plus 1.42 percent, with consensus revenue of 100.18 billion dollars. Cardinal Health also has a Zacks Rank of 2 and an Earnings ESP of plus 1.24 percent, with fiscal fourth-quarter revenue pegged at 65.61 billion dollars. ACADIA Pharmaceuticals rounds out the list with a Zacks Rank of 2 and an Earnings ESP of plus 25.00 percent, driven by expected growth from Daybue and Nuplazid.

Morgan Stanley strategists say US companies integrating artificial intelligence are well positioned for stronger profit margins this earnings season. The team led by Michael Wilson expects about 100 basis points of net-margin expansion through 2027 tied to AI adoption, with margin expectations improving most clearly for firms where AI is central to their investment thesis and pricing power is neutral to strong. Wilson noted that the outlook for AI adopters is increasingly compelling, especially in industries often seen as vulnerable, including transports, software and services, and professional services. Stocks such as Halliburton, Bank of America, CVS Health, and NextEra Energy are among prime beneficiaries, while Alphabet, Meta Platforms, and Nvidia also continue to screen strongly. Wilson said adoption is moving from experimentation to measurable enterprise value, with about 40% of AI adopters citing at least one quantifiable benefit so far this earnings season, up from 21% a year earlier, and companies reporting a net productivity increase of nearly 10% on average over the past year.

Victory Capital's RS Large Cap Value Strategy highlighted CVS Health Corporation as a beneficiary of improving execution and a favorable payer margin outlook in its second-quarter 2026 investor letter. The strategy initiated its position in early 2025 after shares fell due to prior management's aggressive Medicare Advantage expansion, which drove the Health Care Benefits segment's medical benefit ratio from 84.0% in 2022 to 92.5% in 2024 and compressed operating margins from 6.9% to 0.2%. During the second quarter, CVS reported strong first-quarter results, raised full-year guidance, and saw S&P revise its credit outlook from negative to stable, while the Centers for Medicare & Medicaid Services finalized a 2.5% rate increase for 2027, well above the initially proposed 0.1%, and utilization data pointed to moderating medical cost trends. The combination of higher reimbursement and easing cost pressures is expected to support a meaningful recovery in payer margins, with a credible path to earnings growth over the next two to three years, though the strategy trimmed its position opportunistically to fund other ideas. CVS Health shares closed at $110.60 on July 21, 2026, with a one-month return of 8.57% and a 52-week gain of 78.82%, giving the company a market capitalization of $141.12 billion.

CVS Health and Pfizer are trading at forward earnings multiples that analysts describe as absurdly cheap against a backdrop of improving sector fundamentals. CVS closed at $103.61 on July 6, 2026, up 56.84% over 12 months, yet carries a forward P/E of 14 after raising its full-year adjusted EPS guidance to a range of $7.30 to $7.50. Pfizer traded at $24.08 on July 7, 2026, with a forward P/E of 8 and a 7.2% dividend yield, supported by a pipeline that includes roughly 20 pivotal studies starting in 2026 and obesity assets from its approximately $7 billion Metsera acquisition. Both companies posted first-quarter 2026 earnings beats, with CVS delivering adjusted EPS of $2.57 against a $2.21 consensus and Pfizer reporting adjusted diluted EPS of $0.75 versus a $0.72 consensus. Morningstar’s 2026 outlook flagged US healthcare as one of the few sectors still offering broad value, while PineBridge’s 2026 Equity Outlook noted that new pricing agreements and a 15% cap on pharmaceutical imports have reduced tail risks.

CVS Health closed at $110.60, a 2.78% gain that surpassed the S&P 500's 0.89% advance. The drugstore chain and pharmacy benefits manager has risen 6.23% over the past month, exceeding the Medical sector's 4.77% gain and the S&P 500's 0.63% decline. The company is scheduled to report earnings on August 5, 2026, with analysts expecting earnings per share of $1.87, a 3.31% increase from the same quarter last year, and quarterly revenue of $100.18 billion, up 1.28%. For the full year, the Zacks Consensus Estimates project earnings of $7.46 per share and revenue of $409 billion, representing increases of 10.52% and 1.72%, respectively. CVS Health currently carries a Zacks Rank of 2, or Buy, and trades at a forward price-to-earnings ratio of 14.43, a discount to the industry average of 15.64.

CVS Health has opened its first pharmacy-focused CVS Pharmacy in Houston, introducing a smaller neighborhood format designed to expand access to pharmacy care. The company plans to roll out nearly 20 similar locations across the U.S., including additional sites in the Houston area. The new format features a 3,000-square-foot footprint and a tighter product mix centered on prescriptions, immunizations, and pharmacist-led services rather than broad retail. This move is part of CVS Health's effort to realign its retail footprint and respond to changing consumer preferences for in-person pharmacy services.

CVS Health's board approved a quarterly dividend of US$0.665 per share, payable on August 3, 2026, to shareholders of record as of July 23, 2026. Aetna leadership highlighted the clinical importance of GLP-1 weight-loss drugs for diabetes and obesity care, reinforcing perceptions of CVS Health's evolving role across insurance, pharmacy, and care delivery. The company's narrative projects $453.7 billion revenue and $10.7 billion earnings by 2029, requiring 3.8% yearly revenue growth and about a $7.8 billion earnings increase from $2.9 billion today. Five fair value estimates from the Simply Wall St Community range widely from about US$104 to US$294 per share, reflecting divergent views on upside.

UnitedHealth Group raised its full-year adjusted earnings outlook after second-quarter profit exceeded Wall Street expectations, sending shares up as much as 10.3% in their largest intraday gain since April. The company now expects adjusted earnings of $19.50 to $20 per share this year, up from a prior forecast of more than $18.25 and above analyst estimates. A closely watched measure of medical costs also performed better than projected, while quarterly profit topped the highest estimate in a Bloomberg survey. Chief Financial Officer Wayne DeVeydt said improving medical-cost trends in the first half gave the company greater confidence to raise its outlook, and the updated forecast could provide a starting point for increasing profits next year at the company's historical target rate of 13% to 16% average annual earnings-per-share growth. Shares of Humana and CVS Health also advanced following the report.

CVS Health stock currently trades at a trailing price-to-earnings ratio of 46.0, but based on consensus earnings estimates for 2027, that same share price of about $105.91 represents a multiple of just 12.6 times. That forward multiple is a 73% discount from today's trailing figure, effectively meaning patient investors are buying the business two years out at a far lower valuation. Analysts forecast revenue growth of about 2.2% annually, which is below recent actual growth rates of 7.6% over the last twelve months and 6.2% in the most recent quarter, suggesting estimates could prove conservative. The consensus earnings forecast of about $7.43 per share for this year falls within management's raised guidance of $7.30 to $7.50, supported by margin recovery in the Health Care Benefits segment where Aetna drove over $1 billion of year-over-year adjusted operating income improvement. If the market values those 2027 earnings at about 29.3 times, roughly halfway between the current trailing multiple and the 12.6 times floor, the stock could be about 132% higher than today.

Aetna's second quarterly provider survey reveals that the average provider-payer trust score increased to 6.1 out of 10, up from 5.4 in the first quarter, with 38% of providers now ranking payers 8 or higher. The study, conducted by Morning Consult among 723 U.S. providers, found that 52% agree payers consistently deliver on promises, a 16-percentage-point jump, while 56% say payers provide clear coverage information, up 12 points. Providers continue to rank administrative burden as their top challenge, with 84% pointing to managing patient records or prior authorization, and more than 30% expect technology-enabled solutions to save over an hour daily. Additionally, 68% cite interoperability as their top technology challenge, and 71% agree that payer digital tools help patients better understand benefits and care options.

CVS Caremark has reached a settlement agreement with the Federal Trade Commission to resolve litigation and investigations related to its pharmacy benefits management and affiliated pharmacy businesses. The settlement addresses a September 2024 lawsuit alleging anticompetitive rebating practices that inflated insulin list prices and harmed patients. Under the agreement, CVS Caremark will implement reforms including aligning member cost sharing with net drug costs, moving away from rebate guarantees and spread pricing, expanding transparency on drug pricing and broker compensation, capping insulin costs at $25 per month, promoting point-of-sale rebate passthrough, delinking manufacturer compensation from list prices, and transitioning to acquisition-based reimbursement for independent pharmacies. The company will also count eligible TrumpRx discount program purchases toward deductibles and out-of-pocket maximums, subject to regulatory conditions. CVS Caremark will begin implementing the provisions according to timelines set with the FTC.

CVS Health has expanded its GLP-1 support programs across pharmacies, MinuteClinic, and virtual channels while affirming a quarterly dividend of $0.665 per share. The stock has delivered a 90-day price return of 36.43% and a one-year total shareholder return of 70.56%, pushing shares near a 52-week high. At a last close of $105.90, one narrative-based fair value estimate stands at $107.73, suggesting the stock is slightly undervalued, though its current price-to-earnings ratio of 46.1x sits above the US healthcare industry average of 25x and its own fair ratio of 40.6x. The company continues to benefit from rising demand driven by an aging population and higher chronic disease prevalence, but faces potential headwinds from elevated medical cost trends and pharmacy reimbursement pressure.

Health insurance provider stocks tracked by this publication posted a strong first quarter, with revenues beating analyst consensus estimates by 1.4% and next-quarter revenue guidance coming in line. As a group, share prices have risen 37.4% on average since the latest earnings results. Cencora reported revenues of $78.36 billion, up 3.8% year on year but falling short of expectations by 3.9%, leaving its stock flat. CVS Health delivered the biggest beat, with revenues of $100.4 billion up 6.2% year on year and exceeding estimates by 6.3%, driving a 29.2% stock gain. Molina Healthcare's revenues of $10.8 billion, down 3.1% year on year, met expectations but its full-year revenue guidance missed significantly, yet the stock surged 52.6%. Humana's revenues of $39.65 billion, up 23.5% year on year, met estimates and its full-year EPS guidance beat, propelling a 70.4% stock increase. Clover Health achieved the fastest revenue growth at 62% year on year to $749.2 million, beating estimates by 4.8%, and its stock jumped 65.9%.